Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Trillium stock

Article Index

Why Trillium (Nasdaq: TRIL) Stock Is Today's Top Biotech Buy

TRIL stock

Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.

You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer.

Here's how the treatment works, and how it could make TRIL stock the next great biotech blockbuster...

These Promising Cancer Therapies Are a Biotech "Triple Play"

On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.

Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.

And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.

It's clear that investors can do very well with the right cancer drug.

But there, of course, is the rub: Finding the right cancer drug is not so easy.

I'm about to show you three companies - all sound investments - running strong in the race to fight this scourge, and the one that could very well take the prize...